A Network of Epigenomic and Transcriptional Cooperation Encompassing an Epigenomic Master Regulator in Cancer
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Cellular Responses to Erbb-2 Overexpression in Human Mammary Luminal Epithelial Cells: Comparison of Mrna and Protein Expression
British Journal of Cancer (2004) 90, 173 – 181 & 2004 Cancer Research UK All rights reserved 0007 – 0920/04 $25.00 www.bjcancer.com Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression SL White1, S Gharbi1, MF Bertani1, H-L Chan1, MD Waterfield1 and JF Timms*,1 1 Ludwig Institute for Cancer Research, Wing 1.1, Cruciform Building, Gower Street, London WCIE 6BT, UK Microarray analysis offers a powerful tool for studying the mechanisms of cellular transformation, although the correlation between mRNA and protein expression is largely unknown. In this study, a microarray analysis was performed to compare transcription in response to overexpression of the ErbB-2 receptor tyrosine kinase in a model mammary luminal epithelial cell system, and in response to the ErbB-specific growth factor heregulin b1. We sought to validate mRNA changes by monitoring changes at the protein level using a parallel proteomics strategy, and report a surprisingly high correlation between transcription and translation for the subset of genes studied. We further characterised the identified targets and relate differential expression to changes in the biological properties of ErbB-2-overexpressing cells. We found differential regulation of several key cell cycle modulators, including cyclin D2, and downregulation of a large number of interferon-inducible genes, consistent with increased proliferation of the ErbB-2- overexpressing cells. Furthermore, differential expression of genes involved in extracellular matrix modelling and cellular adhesion was linked to altered adhesion of these cells. Finally, we provide evidence for enhanced autocrine activation of MAPK signalling and the AP-1 transcription complex. -
KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations Xiaoni Liu1,2, Shang-Min Zhang1, Meaghan K
Published OnlineFirst December 6, 2018; DOI: 10.1158/1535-7163.MCT-18-0395 Cancer Biology and Translational Studies Molecular Cancer Therapeutics KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations Xiaoni Liu1,2, Shang-Min Zhang1, Meaghan K. McGeary1,2, Irina Krykbaeva1,2, Ling Lai3, Daniel J. Jansen4, Stephen C. Kales4, Anton Simeonov4, Matthew D. Hall4, Daniel P. Kelly3, Marcus W. Bosenberg1,2,5, and Qin Yan1 Abstract Tumor heterogeneity is a major challenge for cancer elevated KDM5B expression, melanoma cells shift toward a À treatment, especially due to the presence of various sub- more drug-tolerant, CD34 state upon exposure to BRAF populations with stem cell or progenitor cell properties. inhibitor or combined BRAF inhibitor and MEK inhibitor þ À þ In mouse melanomas, both CD34 p75 (CD34 )and treatment. KDM5B loss or inhibition shifts melanoma cells À À À þ CD34 p75 (CD34 ) tumor subpopulations were charac- to the more BRAF inhibitor–sensitive CD34 state. These terized as melanoma-propagating cells (MPC) that exhibit results support that KDM5B is a critical epigenetic regulator some of those key features. However, these two subpopula- that governs the transition of key MPC subpopulations tions differ from each other in tumorigenic potential, with distinct drug sensitivity. This study also emphasizes ability to recapitulate heterogeneity, and chemoresistance. the importance of continuing to advance our understand- þ À In this study, we demonstrate that CD34 and CD34 ing of intratumor heterogeneity and ultimately develop V600E subpopulations carrying the BRAF mutation confer novel therapeutics by altering the heterogeneous character- differential sensitivity to targeted BRAF inhibition. -
High KDM1A Expression Associated with Decreased CD8+T Cells Reduces the Breast Cancer Survival Rate in Patients with Breast Cancer
Journal of Clinical Medicine Article High KDM1A Expression Associated with Decreased CD8+T Cells Reduces the Breast Cancer Survival Rate in Patients with Breast Cancer Hyung Suk Kim 1 , Byoung Kwan Son 2 , Mi Jung Kwon 3, Dong-Hoon Kim 4,* and Kyueng-Whan Min 5,* 1 Department of Surgery, Division of Breast Surgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri 11923, Korea; [email protected] 2 Department of Internal Medicine, Eulji Hospital, Eulji University School of Medicine, Seoul 03181, Korea; [email protected] 3 Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Korea; [email protected] 4 Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Korea 5 Department of Pathology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri 11923, Korea * Correspondence: [email protected] (D.-H.K.); [email protected] (K.-W.M.); Tel.: +82-2-2001-2392 (D.-H.K.); +82-31-560-2346 (K.-W.M.); Fax: +82-2-2001-2398 (D.-H.K.); Fax: +82-2-31-560-2402 (K.-W.M.) Abstract: Background: Lysine-specific demethylase 1A (KDM1A) plays an important role in epige- netic regulation in malignant tumors and promotes cancer invasion and metastasis by blocking the immune response and suppressing cancer surveillance activities. The aim of this study was to analyze Citation: Kim, H.S.; Son, B.K.; Kwon, survival, genetic interaction networks and anticancer immune responses in breast cancer patients M.J.; Kim, D.-H.; Min, K.-W. High with high KDM1A expression and to explore candidate target drugs. -
KLF2 Induced
UvA-DARE (Digital Academic Repository) The transcription factor KLF2 in vascular biology Boon, R.A. Publication date 2008 Link to publication Citation for published version (APA): Boon, R. A. (2008). The transcription factor KLF2 in vascular biology. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:23 Sep 2021 Supplementary data: Genes induced by KLF2 Dekker et al. LocusLink Accession Gene Sequence Description Fold p-value ID number symbol change (FDR) 6654 AK022099 SOS1 cDNA FLJ12037 fis, clone HEMBB1001921. 100.00 5.9E-09 56999 AF086069 ADAMTS9 full length insert cDNA clone YZ35C05. 100.00 1.2E-09 6672 AF085934 SP100 full length insert cDNA clone YR57D07. 100.00 6.7E-13 9031 AF132602 BAZ1B Williams Syndrome critical region WS25 mRNA, partial sequence. -
Imidazopyridines As Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human Ipscs
Article Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCs Yasamin Dabiri, Rodrigo A. Gama- Brambila, Katerina Taskova, ..., Jichang Wang, Miguel A. Andrade-Navarro, Xinlai Cheng [email protected] HIGHLIGHTS O4I3 supports the maintenance and generation of human iPSCs O4I3 is a potent H3K4 demethylase KDM5 inhibitor in vitro and in cells KDM5A, but not KDM5B, serves as an epigenetic barrier of reprogramming Chemical or genetic inhibition of KDM5A tends to promote the reprogramming efficiency Dabiri et al., iScience 12,168– 181 February 22, 2019 ª 2019 The Author(s). https://doi.org/10.1016/ j.isci.2019.01.012 Article Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCs Yasamin Dabiri,1 Rodrigo A. Gama-Brambila,1 Katerina Taskova,2,3 Kristina Herold,4 Stefanie Reuter,4 James Adjaye,5 Jochen Utikal,6 Ralf Mrowka,4 Jichang Wang,7 Miguel A. Andrade-Navarro,2,3 and Xinlai Cheng1,8,* SUMMARY Pioneering human induced pluripotent stem cell (iPSC)-based pre-clinical studies have raised safety concerns and pinpointed the need for safer and more efficient approaches to generate and maintain patient-specific iPSCs. One approach is searching for compounds that influence pluripotent stem cell reprogramming using functional screens of known drugs. Our high-throughput screening of drug-like hits showed that imidazopyridines—analogs of zolpidem, a sedative-hypnotic drug—are able to improve reprogramming efficiency and facilitate reprogramming of resistant human primary fibro- blasts. The lead compound (O4I3) showed a remarkable OCT4 induction, which at least in part is 1Institute of Pharmacy and due to the inhibition of H3K4 demethylase (KDM5, also known as JARID1). -
Foamy Viral Vector Integration Sites in SCID-Repopulating Cells After MGMTP140K-Mediated in Vivo Selection
Gene Therapy (2015) 22, 591–595 © 2015 Macmillan Publishers Limited All rights reserved 0969-7128/15 www.nature.com/gt SHORT COMMUNICATION Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selection ME Olszko1, JE Adair2, I Linde1,DTRae1, P Trobridge1, JD Hocum1, DJ Rawlings3, H-P Kiem2 and GD Trobridge1,4 Foamy virus (FV) vectors are promising for hematopoietic stem cell (HSC) gene therapy but preclinical data on the clonal composition of FV vector-transduced human repopulating cells is needed. Human CD34+ human cord blood cells were transduced with an FV vector encoding a methylguanine methyltransferase (MGMT)P140K transgene, transplanted into immunodeficient NOD/SCID IL2Rγnull mice, and selected in vivo for gene-modified cells. The retroviral insertion site profile of repopulating clones was examined using modified genomic sequencing PCR. We observed polyclonal repopulation with no evidence of clonal dominance even with the use of a strong internal spleen focus forming virus promoter known to be genotoxic. Our data supports the use of FV vectors with MGMTP140K for HSC gene therapy but also suggests additional safety features should be developed and evaluated. Gene Therapy (2015) 22, 591–595; doi:10.1038/gt.2015.20; published online 19 March 2015 INTRODUCTION Here we examined clonality and retroviral insertion sites (RIS) of Retroviral vectors derived from the foamy viruses (FVs) efficiently FV vectors in human SCID-repopulating cells after in vivo selection. transduce hematopoietic stem cells (HSCs) and are promising for use in HSC gene therapy.1 One challenge for HSC gene therapy is that some diseases like hemoglobinopathies require high RESULTS AND DISCUSSION percentages of gene-marked cells in order to achieve therapeutic Our goal was to investigate the genotoxicity of FV vectors in the correction. -
Neuro-Oncology Advances 1 1(1), 1–14, 2019 | Doi:10.1093/Noajnl/Vdz042 | Advance Access Date 5 November 2019
applyparastyle "fig//caption/p[1]" parastyle "FigCapt" applyparastyle "fig" parastyle "Figure" Neuro-Oncology Advances 1 1(1), 1–14, 2019 | doi:10.1093/noajnl/vdz042 | Advance Access date 5 November 2019 PELP1 promotes glioblastoma progression by enhancing Wnt/β-catenin signaling Gangadhara R. Sareddy, Uday P. Pratap, Suryavathi Viswanadhapalli, Prabhakar Pitta Venkata, Binoj C. Nair, Samaya Rajeshwari Krishnan, Siyuan Zheng, Andrea R. Gilbert, Andrew J. Brenner, Darrell W. Brann, and Ratna K. Vadlamudi Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, Texas (G.R.S., U.P.P., S.V., P.P.V., B.C.N., S.R.K., R.K.V.); Greehey Children’s Cancer Research Institute, University of Texas Health San Antonio, San Antonio, Texas (S.Z.); Department of Pathology and Laboratory Medicine, University of Texas Health San Antonio, San Antonio, Texas (A.R.G.); Hematology & Oncology, University of Texas Health San Antonio, San Antonio, Texas (A.J.B.); Mays Cancer Center, University of Texas Health San Antonio, San Antonio, Texas (G.R.S., S.Z., A.J.B., R.K.V.); Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, Georgia (D.W.B.) Correspondence Author: Ratna K. Vadlamudi, Department of Obstetrics and Gynecology, 7703 Floyd Curl Drive, University of Texas Health San Antonio, San Antonio, TX 78229 ([email protected]). Abstract Background: Glioblastoma (GBM) is a deadly neoplasm of the central nervous system. The molecular mechanisms and players that contribute to GBM development is incompletely understood. Methods: The expression of PELP1 in different grades of glioma and normal brain tissues was analyzed using immunohistochemistry on a tumor tissue array. -
GABPA Is a Master Regulator of Luminal Identity and Restrains Aggressive Diseases in Bladder Cancer
Cell Death & Differentiation (2020) 27:1862–1877 https://doi.org/10.1038/s41418-019-0466-7 ARTICLE GABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer 1,2,3 3,4 5 2,5 5 3 5 5 Yanxia Guo ● Xiaotian Yuan ● Kailin Li ● Mingkai Dai ● Lu Zhang ● Yujiao Wu ● Chao Sun ● Yuan Chen ● 5 6 3 1,2 1,2 3,7 Guanghui Cheng ● Cheng Liu ● Klas Strååt ● Feng Kong ● Shengtian Zhao ● Magnus Bjorkhölm ● Dawei Xu 3,7 Received: 3 June 2019 / Revised: 20 November 2019 / Accepted: 21 November 2019 / Published online: 4 December 2019 © The Author(s) 2019. This article is published with open access Abstract TERT promoter mutations occur in the majority of glioblastoma, bladder cancer (BC), and other malignancies while the ETS family transcription factors GABPA and its partner GABPB1 activate the mutant TERT promoter and telomerase in these tumors. GABPA depletion or the disruption of the GABPA/GABPB1 complex by knocking down GABPB1 was shown to inhibit telomerase, thereby eliminating the tumorigenic potential of glioblastoma cells. GABPA/B1 is thus suggested as a cancer therapeutic target. However, it is unclear about its role in BC. Here we unexpectedly observed that GABPA ablation 1234567890();,: 1234567890();,: inhibited TERT expression, but robustly increased proliferation, stem, and invasive phenotypes and cisplatin resistance in BC cells, while its overexpression exhibited opposite effects, and inhibited in vivo metastasizing in a xenograft transplant model. Mechanistically, GABPA directly activates the transcription of FoxA1 and GATA3, key transcription factors driving luminal differentiation of urothelial cells. Consistently, TCGA/GEO dataset analyses show that GABPA expression is correlated positively with luminal while negatively with basal signatures. -
Angiogenic Patterning by STEEL, an Endothelial-Enriched Long
Angiogenic patterning by STEEL, an endothelial- enriched long noncoding RNA H. S. Jeffrey Mana,b, Aravin N. Sukumara,b, Gabrielle C. Lamc,d, Paul J. Turgeonb,e, Matthew S. Yanb,f, Kyung Ha Kub,e, Michelle K. Dubinskya,b, J. J. David Hob,f, Jenny Jing Wangb,e, Sunit Dasg,h, Nora Mitchelli, Peter Oettgeni, Michael V. Seftonc,d,j, and Philip A. Marsdena,b,e,f,1 aInstitute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada; bKeenan Research Centre for Biomedical Science in the Li Ka Shing Knowledge Institute, St. Michael’s Hospital, University of Toronto, Toronto, ON M5B 1T8, Canada; cDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON M5S 3E2, Canada; dInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, Canada; eDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada; fDepartment of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada; gArthur and Sonia Labatt Brain Tumour Research Institute, Hospital for SickKids, University of Toronto, Toronto, ON M5G 1X8, Canada; hDivision of Neurosurgery and Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, University of Toronto, Toronto, ON M5B 1W8, Canada; iDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115; and jDepartment of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON M5S 3E5, Canada Edited by Napoleone Ferrara, University of California, San Diego, La Jolla, CA, and approved January 24, 2018 (received for review August 28, 2017) Endothelial cell (EC)-enriched protein coding genes, such as endothelial formation in vitro and blood vessel formation in vivo. -
Mutation Signatures and Mutable Motifs in Cancer Research
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/117709/ This is the author’s version of a work that was submitted to / accepted for publication. Citation for final published version: Rogozin, Igor B., Pavlov, Youri I., Goncearenco, Alexander, De, Subhajyoti, Lada, Artem G., Poliakov, Eugenia, Panchenko, Anna R. and Cooper, David N. 2018. Mutational signatures and mutable motifs in cancer genomes. Briefings in Bioinformatics 19 (6) , pp. 1085-1101. 10.1093/bib/bbx049 file Publishers page: http://dx.doi.org/10.1093/bib/bbx049 <http://dx.doi.org/10.1093/bib/bbx049> Please note: Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper. This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders. Mutational signatures and mutable motifs in cancer genomes Igor B. Rogozin1, Youri I. Pavlov2,3, Alexander Goncearenco1, Subhajyoti De4, Artem G. Lada5, Eugenia Poliakov6, Anna R. Panchenko1, David N. Cooper7 1 National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA 2 Eppley Institute for -
Systems Biology Lecture Outline (Systems Biology) Michael K
Spring 2019 – Epigenetics and Systems Biology Lecture Outline (Systems Biology) Michael K. Skinner – Biol 476/576 CUE 418, 10:35-11:50 am, Tuesdays & Thursdays January 22 & 29, 2019 Weeks 3 and 4 Systems Biology (Components & Technology) Components (DNA, Expression, Cellular, Organ, Physiology, Organism, Differentiation, Development, Phenotype, Evolution) Technology (Genomics, Transcriptomes, Proteomics) (Interaction, Signaling, Metabolism) Omics (Data Processing and Resources) Required Reading ENCODE (2012) ENCODE Explained. Nature 489:52-55. Tavassoly I, Goldfarb J, Iyengar R. (2018) Essays Biochem. 62(4):487-500. Literature Sundaram V, Wang T. Transposable Element Mediated Innovation in Gene Regulatory Landscapes of Cells: Re-Visiting the "Gene-Battery" Model. Bioessays. 2018 40(1). doi: 10.1002/bies.201700155. Abil Z, Ellefson JW, Gollihar JD, Watkins E, Ellington AD. Compartmentalized partnered replication for the directed evolution of genetic parts and circuits. Nat Protoc. 2017 Dec;12(12):2493- 2512. Filipp FV. Crosstalk between epigenetics and metabolism-Yin and Yang of histone demethylases and methyltransferases in cancer. Brief Funct Genomics. 2017 Nov 1;16(6):320-325. Chen Z, Li S, Subramaniam S, Shyy JY, Chien S. Epigenetic Regulation: A New Frontier for Biomedical Engineers. Annu Rev Biomed Eng. 2017 Jun 21;19:195-219. Hollick JB. Paramutation and related phenomena in diverse species. Nat Rev Genet. 2017 Jan;18(1):5-23. Macovei A, Pagano A, Leonetti P, Carbonera D, Balestrazzi A, Araújo SS. Systems biology and genome-wide approaches to unveil the molecular players involved in the pre-germinative metabolism: implications on seed technology traits. Plant Cell Rep. 2017 May;36(5):669-688. Bagchi DN, Iyer VR. -
The Human Proteome Co-Regulation Map Reveals Functional Relationships Between Proteins
bioRxiv preprint doi: https://doi.org/10.1101/582247; this version posted March 19, 2019. The copyright holder for this preprint (which was 19/03/2019not certified by peer review) is the author/funder, who hasNBT_manuscript_revised granted bioRxiv a license - toGoogle display Docs the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 1 The human proteome co-regulation map reveals functional relationships 2 between proteins 3 Georg Kustatscher1 *, Piotr Grabowski2 *, Tina A. Schrader3 , Josiah B. Passmore3 , Michael 4 Schrader3 , Juri Rappsilber1,2# 5 1 Wellcome Centre for Cell Biology, University of Edinburgh, Edinburgh EH9 3BF, UK 6 2 Bioanalytics, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, 7 Germany 8 3 Biosciences, University of Exeter, Exeter EX4 4QD, UK 9 * Equal contribution 10 # Communicating author: [email protected] 11 Submission as Resource article. 12 The annotation of protein function is a longstanding challenge of cell biology that 13 suffers from the sheer magnitude of the task. Here we present ProteomeHD, which 14 documents the response of 10,323 human proteins to 294 biological perturbations, 15 measured by isotope-labelling mass spectrometry. Using this data matrix and robust 16 machine learning we create a co-regulation map of the cell that reflects functional 17 associations between human proteins. The map identifies a functional context for 18 many uncharacterized proteins, including microproteins that are difficult to study with 19 traditional methods. Co-regulation also captures relationships between proteins 20 which do not physically interact or co-localize. For example, co-regulation of the 21 peroxisomal membrane protein PEX11β with mitochondrial respiration factors led us 22 to discover a novel organelle interface between peroxisomes and mitochondria in 23 mammalian cells.